Clinical trials: Basal Cell Carcinoma
Carcinoma
Study Evaluating the Efficacy and Safety of 0.05% Ingenol Mebutate (Picato® 500) in the Treatment of Basal Cell Carcinoma
Basal cell carcinomas (BCCs) are the most common form of cancer. The treatment of BCC can be surgical or topical for the low-risk subtypes. Topical treatments used for BCC are imiquimod and photodynamic therapy (PDT).
- Trial name
- PICABAS (NCT03546166)
- Testing
- Picato 0.05% Topical Gel
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Melanoma, Squamous Cell Carcinoma of the Head and Neck
Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)
The purpose of this study is to test the safety of a course of injections containing Poly-ICLC in patients with advanced solid tumors that can be easily and safely reached with a needle.
- Conditions
- Melanoma, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma of the Skin, Sarcoma of the Skin
- Trial name
- Hiltonol (NCT01984892)
- Testing
- Poly-ICLC
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Nina Bhardwaj
Squamous Cell Carcinoma of Head and Neck, Basal Cell Carcinoma of Skin
Intraoperative Assessment of Surgical Margins Using Confocal Microscopy in Comparison With Reference Extemporaneous Examination
Study to evaluate the use of confocal microscopy for detecting resection margins in patients undergoing surgery for basal cell carcinoma of skin and squamous Cell Carcinoma of Head and Neck
- Trial name
- HISTOBLOC (NCT05935995)
- Testing
- microscopy confocal (Histolog Scanner)
- Where
- France
- Volunteers
- 42 people
- Sponsor
- Institut de Cancérologie de Lorraine
Basal Cell Carcinoma
A Study of IO103 in Montanide Adjuvant for Basal Cell Carcinoma
A single center, open-label, phase IIa, single arm, window of opportunity trial with IO103 and Montanide adjuvant in patients with surgically resectable BCC.
- Trial name
- NCT03714529
- Testing
- PD-L1
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- Herlev and Gentofte Hospital
Solid Cancers
A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
This is a two stage, Phase Ib study designed to describe the pharmacokinetics of GDC-0449 in patients with advanced solid tumors that are refractory to treatment or for whom no standard therapy exists.
- Trial name
- NCT00968981
- Testing
- GDC-0449
- Volunteers
- 67 people
- Sponsor
- Genentech, Inc.
Non-melanomatous Skin Cancer
Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer
RATIONALE: Biological therapies such as imiquimod use different ways to stimulate the immune system and stop cancer cells from growing.
- Trial name
- NCT00066872
- Testing
- imiquimod, conventional surgery
- Where
- 3 sites in United Kingdom
- Volunteers
- 500 people
- Sponsor
- Queen's Medical Center
Skin Lesions, Melanocytic Nevi
Evaluating an Artificial Intelligence Tool to Help Primary Care Doctors Diagnose Skin Conditions.
This study aims to determine if an artificial intelligence (AI) medical device can help primary care doctors more accurately identify and manage various skin conditions.
- Conditions
- Skin Lesions, Melanocytic Nevi, Melanoma (Skin Cancer), Basal Cell Carcinoma of Skin
- Trial name
- LegitHealth PH (NCT07428941)
- Testing
- AI-based medical device for aided diagnosis in dermatological conditions
- Where
- Spain
- Volunteers
- 9 people
- Sponsor
- AI Labs Group S.L
Metastatic Basal Cell Carcinoma, Locally Advanced Basal Cell Carcinoma
Relationship Between Pharmacokinetics and Safety of Vismodegib - OPTIVISMO-1
Vismodegib (ERIVEDGE®) at the standard dose of 150 mg/day orally is indicated for the treatment of advanced Basal Cell Carcinoma (BCC) and is associated with many adverse effects.
- Trial name
- OPTIVISMO-1 (NCT03610022)
- Testing
- Treatment with vismodegib
- Where
- France
- Volunteers
- 27 people
- Sponsor
- University Hospital, Bordeaux
Basal Cell Carcinoma
Assessment of the Clinic-pathological Correlation of Basal Cell Carcinoma
Assessment of the concordance of the initial clinical and histological diagnosis and to explore its prognostic impact in terms of risk of recurrence.
- Trial name
- CAC-CBC (NCT02825511)
- Where
- 17 sites in France
- Volunteers
- 2,738 people
- Sponsor
- University Hospital, Bordeaux
Breast Cancer, Head and Neck Cancer
S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors
RATIONALE: Vandetanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Breast Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT00937417
- Testing
- docetaxel, vandetanib, proteomic profiling
- Sponsor
- SWOG Cancer Research Network
Basal Cell Carcinoma
A Clinical Trial of Dermacorder for Detecting Malignant Skin Lesions
The Dermacorder measures the electric field in the skin. Malignant skin lesions disrupt the skin's normal electric field and this abnormal electric field can be detected by the Dermacorder.
- Trial name
- Dermacorder (NCT01014819)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- UCSF Benioff Children's Hospital Oakland
Squamous Cell Carcinoma (SCC), Basal Cell Carcinoma (BCC)
Intraoperative Margin Assessment During Mohs Surgery
The research team will develop an intraoperative handheld device for assessing surgical margins during Mohs surgery. The device technology is based on multimodal optical spectroscopy (MMS), combining three optical spectroscopy…
- Trial name
- NCT02750033
- Testing
- Multimodal Spectroscopy (MMS)
- Sponsor
- Seton Healthcare Family
Carcinoma, Basal Cell, Malignant
Identification of Psychosocial Factors Associated With Diagnostic Delay in Advanced Basal Cell Carcinoma
The aim of this study was to identify psycho-social factors associated with diagnostic delay in advanced basal cell carcinomas. Thus, the objective is to develop recommendations to better identify CBCa populations at risk…
- Trial name
- PSYCHO-CBC (NCT04124796)
- Testing
- Semi-structured interviews
- Where
- France
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Basal Cell Carcinoma (BCC)
Intralesional Cryosurgery for Basal Cell Carcinoma - a Feasibility Study
A feasibility study for the treatment of Basal Cell Carcinoma of the lower extremities in the elderly utilizing intralesional cryosurgery.
- Trial name
- NCT01633515
- Testing
- Intralesional cryotherapy
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Carmel Medical Center
Carcinoma, Basal Cell
HIFU for Treatment of Non-nodular and Recurrent BCC
The overall objective of this study is to demonstrate the safety and efficacy of removal of Basal Cell Carcinoma (BCC) using a new investigational equipment based on high-intensity focused ultrasound.
- Trial name
- BCC-HIFU2101 (NCT05133427)
- Testing
- TOOsonix system ONE-M
- Where
- 2 sites in Denmark
- Volunteers
- 28 people
- Sponsor
- Joergen Serup
Basal Cell Carcinoma
Metvix PDT in Participant With "High Risk" Basal Cell Carcinoma
Photodynamic therapy (PDT) is the selective destruction of abnormal cells through light activation of a photosensitiser in the presence of oxygen. These cells accumulate more photosensitiser than normal cells.
- Trial name
- NCT00473343
- Testing
- Metvix® cream
- Where
- 7 sites in Australia
- Volunteers
- 102 people
- Sponsor
- Galderma R&D
Skin Basal Cell Carcinoma
Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer
This phase 1-2 trial studies how well pembrolizumab with or without vismodegib works in treating patients with skin basal cell cancer that has spread to other places in the body or cannot be removed by surgery.
- Trial name
- NCT02690948
- Testing
- Pembrolizumab, Vismodegib
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Anne Chang
Basal Cell Carcinoma, Squamous Cell Carcinoma of Skin Differentiated
Hydrogen Peroxide Trial to Investigate the Efficacy of 30%H2O2 as a Topical Application Before Definitive Treatment
Previous work suggests that topical treatment with 33% hydrogen peroxide can reduce lesion size and, in about half of patients, can cause complete pathologic response.
- Trial name
- NCT04929535
- Testing
- Hydrogen Peroxide 30 % Topical Solution
- Where
- Canada
- Volunteers
- 51 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Breast Cancer, Head and Neck Cancer
Using Traditional Acupuncture in the Management of Cancer Treatment Related Lymphoedema
RATIONALE: Acupuncture and moxibustion may improve well-being and quality of life in patients with lymphedema caused by breast cancer or head, neck, and throat cancer.
- Conditions
- Breast Cancer, Head and Neck Cancer, Lymphedema
- Trial name
- AMWELL-SL (NCT00828516)
- Testing
- Acupuncture and moxibustion
- Where
- United Kingdom
- Volunteers
- 56 people
- Sponsor
- East and North Hertfordshire NHS Trust
Carcinoma, Basal Cell
Observational Study to Determine the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Locally Advanced Basal Cell Carcinoma (laBCC)
The primary purpose for this multi-center, non-interventional study is to evaluate the duration of response defined as duration from first documented response of complete response (CR) or partial response (PR) until disease…
- Trial name
- NIELS (NCT02674009)
- Testing
- Vismodegib
- Where
- Germany
- Volunteers
- 67 people
- Sponsor
- Hoffmann-La Roche